Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM1 | P11229 | 2/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.41 |
| ▸ | PREP | P48147 | 2/20 | 0.37 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.37 |
| ▸ | GPR119 | Q8TDV5 | 7/20 | 0.36 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 3/20 | 0.35 |
| ▸ | RBP4 | P02753 | 1/20 | 0.33 |
| ▸ | PDE5A | O76074 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4521161 | 0.88 | CHRM2 (0.38) | CHRM1CHRM2CHRM3PREPHSD11B1 | |
| SCHEMBL13711484 | 0.88 | CHRM2 (0.38) | CHRM1CHRM2CHRM3PREPHSD11B1 | |
| SCHEMBL4513186 | 0.87 | MEN1 (0.38) | CHRM1CHRM2CHRM3PREPHSD11B1 | |
| SCHEMBL4515301 | 0.85 | PDK2 (0.40) | CHRM1CHRM2CHRM3PREPHSD11B1 | |
| SCHEMBL4519627 | 0.85 | GPR119 (0.47) | CHRM1CHRM2CHRM3PREPHSD11B1 | |
| SCHEMBL5254908 | 0.72 | HTR2B (0.36) | — | |
| SCHEMBL4511597 | 0.72 | PGR (0.35) | HDAC1 | |
| SCHEMBL3168339 | 0.71 | CHRM2 (0.41) | CHRM1CHRM2CHRM3HSD11B1GPR119 | |
| SCHEMBL3168332 | 0.71 | CHRM2 (0.41) | CHRM1CHRM2CHRM3HSD11B1GPR119 | |
| SCHEMBL12094701 | 0.71 | OPRK1 (0.55) | CHRM1CHRM2CHRM3GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7589104-B2 | Tricyclic-bridged piperidinyline derivatives as §-opioid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-15 | — | — | US | disclosed |
| US-7589104-B2 | Tricyclic-bridged piperidinyline derivatives as §-opioid modulators | JANSSEN PHARMACEUTICA NV (BE) | 2009-09-15 | — | — | US | disclosed |
| EP-1833825-A1 | TRICYCLIC DELTA-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2007-09-19 | — | — | EP | disclosed |
| WO-2006069277-A1 | TRICYCLIC δ-OPIOID MODULATORS | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-29 | — | — | WO | disclosed |
| US-20060135524-A1 | Tricyclic delta-opioid modulators | JANSSEN PHARMACEUTICA N.V. (BE) | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135524-A1 | Tricyclic delta-opioid modulators | OPRD1, OPRK1, OPRL1 | CHRM1 93/4885CHRM2 125/4885CHRM3 85/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.